Osmosis Investment Management UK Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,817 shares of the biopharmaceutical company's stock, valued at approximately $1,757,000.
Other hedge funds have also modified their holdings of the company. Insigneo Advisory Services LLC increased its stake in Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital boosted its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 14 shares during the period. Guardian Wealth Advisors LLC NC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 14 shares during the period. TD Private Client Wealth LLC increased its position in shares of Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock worth $130,000 after acquiring an additional 15 shares in the last quarter. Finally, MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 15 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Regeneron Pharmaceuticals
In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 in the last quarter. Company insiders own 6.97% of the company's stock.
Regeneron Pharmaceuticals Price Performance
NASDAQ REGN opened at $828.50 on Tuesday. The company has a 50 day simple moving average of $701.36 and a 200-day simple moving average of $716.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $85.30 billion, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm posted $12.81 earnings per share. The firm's revenue was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on REGN. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $801.70.
Read Our Latest Stock Analysis on REGN
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
